|
Preclinical characterization of D3S-001, a highly potent, selective, and differentiated covalent inhibitor of KRAS G12C. |
|
|
|
Travel, Accommodations, Expenses - D3 Bio |
|
|
|
Travel, Accommodations, Expenses - WuXi AppTec |
|
|
|
Travel, Accommodations, Expenses - WuXi AppTec |
|
|
|
Travel, Accommodations, Expenses - WuXi AppTec |
|
|
|
Travel, Accommodations, Expenses - WuXi AppTec |
|
|
|
Travel, Accommodations, Expenses - WuXi AppTec |
|
|
|
Travel, Accommodations, Expenses - D3 Bio |
|
|
|
Travel, Accommodations, Expenses - D3 Bio |
|
|
|
Travel, Accommodations, Expenses - D3 Bio |
|
|
|
Travel, Accommodations, Expenses - D3 Bio |
|
|
|
Travel, Accommodations, Expenses - D3 Bio |
|
|
No Relationships to Disclose |
|
|
|
Travel, Accommodations, Expenses - D3 Bio |
|
|
|
Travel, Accommodations, Expenses - D3 Bio |
|
|
|
|
Stock and Other Ownership Interests - D3 Bio |
Travel, Accommodations, Expenses - D3 Bio |
|
|
|
|
Stock and Other Ownership Interests - D3 Bio |
Travel, Accommodations, Expenses - D3 Bio |